AVID BIOSERVICES INC (CDMO)
US05368M1062 - Common Stock
We assign a fundamental rating of 2 out of 10 to CDMO. CDMO was compared to 582 industry peers in the Biotechnology industry. CDMO may be in some trouble as it scores bad on both profitability and health. CDMO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CDMO had negative earnings in the past year.
CDMO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CDMO reported negative net income in multiple years.
In multiple years CDMO reported negative operating cash flow during the last 5 years.
1.2 Ratios
CDMO has a better Return On Assets (-4.40%) than 91.33% of its industry peers.
With an excellent Return On Equity value of -11.13%, CDMO belongs to the best of the industry, outperforming 90.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -11.13% | ||
| ROIC | N/A |
ROA(3y)10.36%
ROA(5y)1.12%
ROE(3y)25.91%
ROE(5y)4.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 8.20%, CDMO is doing good in the industry, outperforming 73.83% of the companies in the same industry.
CDMO's Gross Margin has improved in the last couple of years.
CDMO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 8.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y47.82%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CDMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDMO has more shares outstanding
The number of shares outstanding for CDMO has been increased compared to 5 years ago.
The debt/assets ratio for CDMO has been reduced compared to a year ago.
2.2 Solvency
CDMO has an Altman-Z score of -0.47. This is a bad value and indicates that CDMO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.47, CDMO is in line with its industry, outperforming 58.23% of the companies in the same industry.
CDMO has a Debt/Equity ratio of 0.83. This is a neutral value indicating CDMO is somewhat dependend on debt financing.
The Debt to Equity ratio of CDMO (0.83) is worse than 77.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.47 |
ROIC/WACCN/A
WACC6.89%
2.3 Liquidity
CDMO has a Current Ratio of 0.46. This is a bad value and indicates that CDMO is not financially healthy enough and could expect problems in meeting its short term obligations.
CDMO's Current ratio of 0.46 is on the low side compared to the rest of the industry. CDMO is outperformed by 93.76% of its industry peers.
A Quick Ratio of 0.31 indicates that CDMO may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.31, CDMO is doing worse than 95.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.46 | ||
| Quick Ratio | 0.31 |
3. Growth
3.1 Past
CDMO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1450.00%.
The Revenue has grown by 24.00% in the past year. This is a very strong growth!
CDMO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.74% yearly.
EPS 1Y (TTM)-1450%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
Revenue 1Y (TTM)24%
Revenue growth 3Y35.74%
Revenue growth 5Y22.74%
Sales Q2Q%-11.06%
3.2 Future
CDMO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -25.99% yearly.
The Revenue is expected to grow by 28.94% on average over the next years. This is a very strong growth
EPS Next Y-3338.5%
EPS Next 2Y-359.62%
EPS Next 3Y-25.99%
EPS Next 5YN/A
Revenue Next Year-6.26%
Revenue Next 2Y5.13%
Revenue Next 3Y10.67%
Revenue Next 5Y28.94%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CDMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDMO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CDMO's earnings are expected to decrease with -25.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-359.62%
EPS Next 3Y-25.99%
5. Dividend
5.1 Amount
No dividends for CDMO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVID BIOSERVICES INC
NASDAQ:CDMO (6/14/2024, 7:00:04 PM)
After market: 7.085 0 (0%)7.085
+0.18 (+2.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap449.76M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -11.13% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 8.2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.46 | ||
| Quick Ratio | 0.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1450%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-3338.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)24%
Revenue growth 3Y35.74%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y